Global pharmaceutical company Almirall has collaborated with research group Nanomol, of the Institute of Material Science of Barcelona from the Spanish National Research Council (ICMAB-CSIC), and the Leitat Technology Centre of Nanomedicine to conduct a research project.
The research project, named Nano4Derm, will focus on the development of innovative formulations containing nanoencapsulated active ingredients for the treatment of inflammatory diseases such as acne and psoriasis.
The project aims to develop two types of nanocapsules; quatsomes and polymetic. Researchers are hoping to address current unmet needs of these nanocapsules, such as antimicrobial resistance, to provide improved topical treatments in terms of side effects, skin penetration, and instability of active ingredients.
ICMAB-CSIC and the Leitat Tecnology Center will oversee the development of the different prototypes of nanocapsules containing the active ingredients while Almirall will be responsible for the development of formulations containing the encapsulated actives.